Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 10, 2001 - Issue 6
Submit an article Journal homepage
16
Views
3
CrossRef citations to date
0
Altmetric
Miscellaneous

New developments in the treatment of ovarian cancer

Scott Wadler Department of Oncology, Hofheimer One, Montefiore Medical Center, Bronx, NY 10467, USA, Tel.: +1 718 920 4830; Fax: +1 718 798 7474;, E-mail: [email protected]
Pages 1167-1172 | Published online: 24 Feb 2005

REFERENCES

  • YOUNG RC, WALTON LA, ELLENBERG SS et al: Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N. Engl. J. Med. (1990) 322(15):1021–1027.
  • YOUNG RC: Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer. Semin. arca (2000) 27(3 Suppl. 7):8–10.
  • HOSKINS W, RICE L, RUBIN S: Ovarian cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines. Oncology (1997) 11(6):896–900, 903–904.
  • ALBERTS DS, LIU PY, HANNIGAN EV et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl. j Med. (1996) 335(26):1950–1955.
  • OZOLS R, BUNDY B, FOWLER J et al.: Randomized Phase III trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group study (GOG 158) Soc. Gyrraecol. Omni (2000) 31:72.
  • GORE M, MAINWARING E MACFARLANE V etal.: A randomized study of high versus standard dose carboplatin in patients with advanced epithelial ovarian cancer Am. Soc. Cirri. Oncol (1996) 15:284.
  • JAKOBSEN A: A dose intensity study of carboplatin in ovarian cancer. Int. Oncol (1995) 5 (Suppl. 5):11.

Bibliography

  • ROWINSKY EK, DONEHOWER RC: Paclitaxel (taxol). N Engl. I Med. (1995) 332(15):1004–1014.
  • MCGUIRE WP HOSKINS WJ, BRADY MF et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Eng/. J. Med. (1996) 334(1):1–6.
  • PICCART MJ, BERTELSEN K, JAMES K et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. j. Natl. Cancer Inst. (2000) 92(9):699–708.
  • MUGGIA FM, BRALY PS, BRADY MF et al.: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. j. CM]. Oncol. (2000) 18(1):106–115.
  • NEIJT JP, ENGELHOLM SA, TUXEN MK etal.: Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. j. Oncol. (2000) 18(17):3084–3092.
  • ALBERTS DS: Carboplatin versus cisplatin in ovarian cancer. Semin Oncol. (1995) 22(5 Suppl. 12):88–90.
  • SWENERTON K, JEFFREY J, STUART G etal.: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized Phase III study of the National Cancer Institute of Canada Clinical Trials Group. j. Oncol. (1992) 10(5):718–726.
  • SWENERTON KD, PATER JL: Carboplatin in the treatment of carcinoma of the ovary: the National Cancer Institute of Canada experience. Ovarian Cancer Subcommittee. Sefton. Oncol. (1992) 19(1 Suppl. 2):114–119.
  • ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet (1998) 352(9140):1571–1576.
  • JOLY E HERON JF, KERBRAT P et al.: High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Cynecol. Oncol. (2000) 78(3 Pt 1):361–368.
  • COLEMAN RL, BAGNELL KG, TOWNLEY PM: Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma. Cancer J. Sci. Am. (1997) 3(4):246–253.
  • TEN BOKKEL HUININK WW, VAN WARMERDAM LJ, HELMERHORST TJ, SCHAEFERS MC, BEIJNEN JH, RODENHUIS S: Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. Ann. Oncol. (1997) 8(4):351–354.
  • SCHINK J, WELLER E, HARRIS L et Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial ovarian carcinoma of the ovary results in improved quality-of-life. An Eastern Cooperative Oncology Group Phase II study. Cancer J. Li. kn. (2001) (In press).
  • OZOLS R, BUNDY B, FOWLER J et al.: Randomized Phase III study of cisplatin / paclitaxel versus carboplatin /PAC in optimal stage III epithelial ovarian cancer (CC): A Gynecologic Oncology Group (GOG 158) trial. kn. Soc. Clin. Oncol. (1999) 18:356.
  • DU BOIS A, LUECK H, MEIER W et al.: Cisplatinl paclitaxel vs. carboplatin/ paclitaxel in ovarian cancer: update of an arbeitsgemeinschaft gynaekologische onkologie (AG) study Ain. Soc. Clin. Oncol. (1999) 18: 356.
  • BOOKMAN MA, MCGUIRE WP 3RD, KILPATRICK D et al.: Carboplatin and paclitaxel in ovarian carcinoma: a Phase I study of the Gynecologic Oncology Group. j Clin. Oncol. (1996) 14(6):1895–1902.
  • SPEYER J, HOCHSTER H, RUNOWICZ C etal.: First line therapy of ovarian cancer (OC) with cisplatin and prolonged infusion topotecan. Am. Soc. Clin. Oncol. (1998) 17:350.
  • THIGPEN JT: Dose-intensity in ovariancarcinoma: hold, enough? _J. CM]. Oncol. (1997) 15(4):1291–1293.
  • CREEMERS GJ, BOLIS G, GORE M et al.: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II study. j. Oncol. (1996) 14(12):3056–3061.
  • HOCHSTER H, WADLER S, RUNOWICZ C etal.: Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. j. CM]. Oncol. (1999) 17(8):2553–2561.
  • TEN BOKKEL HUININK W, GORE M, CARMICHAEL J etal.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. j. CM]. Oncol. (1997) 15(6):2183–2193.
  • GORDON AN, GRANAI CO, ROSE PG etal. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. j. Oncol. (2000) 18(17):3093–3100.
  • SAFRA T, GROSHEN S, JEFFERS S et al.: Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Cancer (2001) 91(1):90–100.
  • MUGGIA FM, HAINSWORTH JD, JEFFERS S et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. j. Oncol. (1997) 15(3):987–993.
  • GORDON AN, FLEAGLEJT, GUTHRIE D etal.: Interim analysis of a phase III randomized trial of doxil/caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer. Proc. Am. Soc. Oncol. (2000) 19:380a.
  • MARKMAN M, KENNEDY A, WEBSTER K, PETERSON G, KULP B, BELINSON J: Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/ paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Cynecol. Oncol. (2000) 78(3 Part 1):369–372.
  • LUND B, HANSEN OP, THEILADE K, HANSEN M, NEIJT JP: Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. j. Natl. Cancer Inst. (1994) 86(20):1530–1533.
  • SHAPIRO JD, MILLWARD MJ, PIS CHIN D et al.: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Cynecol. Oncol. (1996) 63(1):89–93.
  • PICCART MJ, GREEN JA, LACAVE AJ etal.: Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized Phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. Oncol. (2000) 18(6):1193–1202.
  • MARKMAN M, KENNEDY A, WEBSTER K et al.: Phase II trial of carboplatin and docetaxel in ovarian and fallopian tube cancers and primary peritoneal carcinoma. Soc. Cynecol. Oncol. (2000) 31:185.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.